专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006120010A3 DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS 审中-公开
标题翻译： DIBENZOCYCLOHEPTANVERBINDUNGEN与药品这些化合物
公开(公告)号：WO2006120010A3
公开(公告)日：2007-01-18
申请号：PCT/EP2006004488
申请日：2006-05-12
申请人： MERCKLE GMBH , LAUFER STEFAN , ALBRECHT WOLFGANG , GREIM CORNELIA , STRIEGEL HANS-GUENTER , TOLLMANN KAROLA
发明人： LAUFER STEFAN , ALBRECHT WOLFGANG , GREIM CORNELIA , STRIEGEL HANS-GUENTER , TOLLMANN KAROLA
IPC分类号： C07D313/12 , A61K31/335 , A61P29/00
CPC分类号： C07D313/12 , C07C225/22 , C07D337/12 , C07D491/044
摘要： The present invention relates to compounds of formula (I), in which R1, R2, R3, R4, X and Y have the meanings indicated in the description. These compounds have immuno-modulating effects, as well as an inhibiting or regulating effect on the release of IL-1ß and/or TNF-a. They can therefore be used for the treatment of diseases associated with a disturbance of the immune system.
摘要翻译：本发明涉及式（I）的化合物，其中R1，R2，R3，R4，X和Y具有在说明书中给出的含义。所述化合物具有免疫调节和IL-1β和/或TNF-α的抑制或调节活性的释放。因此，它们可用于治疗与免疫系统紊乱有关的疾病。

2. 发明申请

WO1992012133A2 ARTHROPODICIDAL CARBOXANILIDES 审中-公开
标题翻译：抗坏血酸羧甲基纤维素
公开(公告)号：WO1992012133A2
公开(公告)日：1992-07-23
申请号：PCT/US1991009172
申请日：1991-12-17
申请人： E.I. DU PONT DE NEMOURS AND COMPANY , HARRISON, Charles, Richard , KRANIS, Kevin, Thomas , STEVENSON, Thomas, Martin
发明人： E.I. DU PONT DE NEMOURS AND COMPANY
IPC分类号： C07D231/54
CPC分类号： C07D495/04 , C07C281/12 , C07D223/20 , C07D225/08 , C07D231/54 , C07D237/26 , C07D245/04 , C07D267/22 , C07D281/18 , C07D313/12 , C07D313/14 , C07D313/20 , C07D337/12 , C07D337/14 , C07D337/16 , C07D401/12 , C07D487/04 , C07D491/04 , C07D513/04
摘要： Compounds of formula (I), wherein Q, X, R , R , R and Z are as defined in the text, including compositions containing said compounds and a method for using them to control arthropods.
摘要翻译：式（I）化合物，其中Q，X，R 1，R 2，R 9和Z如本文所定义，包括含有所述化合物的组合物和使用它们控制节肢动物的方法。

3. 发明申请

WO2002078710A1 過活動膀胱治療剤审中-公开
标题翻译：补救措施为VESICAL HYPERACTIVITY
公开(公告)号：WO2002078710A1
公开(公告)日：2002-10-10
申请号：PCT/JP2002/003167
申请日：2002-03-29
申请人：協和醗酵工業株式会社 , 山形強 , 厚喜薫 , 大野哲司 , 白倉史郎 , 唐沢啓
发明人：山形強 , 厚喜薫 , 大野哲司 , 白倉史郎 , 唐沢啓
IPC分类号： A61K31/55
CPC分类号： C07D495/04 , A61K31/55 , C07D337/12
摘要： Remedies for vesical hyperactivity which contain as the active ingredient tricyclic compounds represented by the following general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 represents hydrogen, optionally substituted lower alkyl, etc.; X1-X2-X3 represents CR5=CR6-CR7=CR8, CR5=CR6-S, etc.; Y represents -CH2S-, SOCH2, etc.; and R2 represents hydrogen, etc.
摘要翻译：含有作为活性成分的由以下通式（I）表示的三环化合物或其药理学上可接受的盐的Vesical多动症的治疗：（I）其中R1表示氢，任选取代的低级烷基等; X1-X2-X3表示CR5 = CR6-CR7 = CR8，CR5 = CR6-S等; Y表示-CH 2 S-，SOCH 2等; R2表示氢等

4. 发明申请

WO00023417A1 NEW COMPOUNDS, THEIR PREPARATION AND USE 审中-公开
标题翻译：新化合物，他们的准备和使用
公开(公告)号：WO00023417A1
公开(公告)日：2000-04-27
申请号：PCT/DK1999/000574
申请日：1999-10-19
IPC分类号： A61K31/192 , A61K31/195 , A61K31/216 , A61K31/335 , A61K31/357 , A61K31/38 , A61K31/423 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/08 , A61P25/28 , A61P43/00 , C07C59/72 , C07C69/00 , C07C69/734 , C07C217/22 , C07C217/54 , C07D263/52 , C07D313/12 , C07D321/12 , C07D337/12 , A61K31/185 , A61K31/215 , C07D263/60
CPC分类号： C07D263/52 , C07C59/72 , C07C69/734 , C07C217/22 , C07C2603/32 , C07D313/12 , C07D321/12 , C07D337/12
摘要： The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
摘要翻译：本发明涉及由式（Ia）表示的化合物。这些化合物可用于治疗和/或预防核受体介导的状态，特别是过氧化物酶体增殖物激活受体（PPAR）。

5. 发明申请

WO1986001203A1 TRYCICLIC OR TETRACYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION CONTAINING THEM 审中-公开
标题翻译： TRYCICLIC或TETRACYCLIC化合物，其制备方法和含有它们的药物组合物
公开(公告)号：WO1986001203A1
公开(公告)日：1986-02-27
申请号：PCT/JP1985000445
申请日：1985-08-09
申请人： DAINIPPON PHARMACEUTICAL CO., LTD. , UNO, Hitoshi , KUROKAWA, Mikio , SATO, Fuminori , HATANO, Naonobu
发明人： DAINIPPON PHARMACEUTICAL CO., LTD.
IPC分类号： C07D213/74
CPC分类号： C07D215/38 , C07D213/74 , C07D239/42 , C07D277/38 , C07D295/15 , C07D337/12 , C07D409/12
摘要： Compounds represented by general formula (I) (wherein A represents alkylene, Y-Z represents formula (II), -CH=CH-, -CH2CH2- or formula (III), R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents phenyl, phenylalkyl, phenylalkenyl, diphenylmethyl, naphthyl, thiazolyl, optionally substituted pyridyl, optionally substituted pyrimidinyl, quinolyl, benzoylalkyl, benzoyl, furoyl, thenoyl, phenyloxycarbonyl, phenyloxysulfonyl or phenylsulfonyl, a represents 2 or 3, b and c each represents 1 or 2, and d represents an integer of 0 to 2, provided that the phenyl, phenyl moiety or naphthyl moiety may be substituted) and salts thereof, processess for their preparation, and medicinal compositions containing them. These compounds show a strong calcium-antagonistic effect, and are therefore useful for prophylaxis and treatment of hypertension and/or ischemic heart diseases.
摘要翻译： PCT No.PCT / JP85 / 00445 Sec。一九八六年四月十日 102（e）日期1986年4月10日PCT提交1985年8月9日PCT公布。公开号WO86 / 01203 日期：1986年2月27日。下式的化合物：其中A表示亚烷基; Y-Z表示 -CH = CH-，-CH2CH2-或R1，R2和R2各自为取代基; R3是氢原子，烷基或烷氧基; R4是苯基，苯基烷基，苯基链烯基，二苯基甲基，萘基，噻唑基，任选取代的吡啶基，任选取代的嘧啶基，喹啉基，苯甲酰基烷基，苯甲酰基，糠酰基，噻吩甲酰基，苯氧基羰基，苯氧基磺酰基或苯基磺酰基; a为2或3，b和c各自为1或2，d为0至2的整数，条件是苯基，苯基部分和萘基可任选被取代，及其药学上可接受的盐，其制备方法及含有该组合物的药物组合物。化合物及其盐显示出有效的钙拮抗活性，可用于预防和治疗高血压和/或缺血性心脏病。

6. 发明申请

WO2004087131A1 鎮咳剤审中-公开
标题翻译：镇咳药
公开(公告)号：WO2004087131A1
公开(公告)日：2004-10-14
申请号：PCT/JP2004/004578
申请日：2004-03-31
申请人：協和醱酵工業株式会社 , 三木一郎 , 石井秀衛
发明人：三木一郎 , 石井秀衛
IPC分类号： A61K31/381
CPC分类号： A61K31/381 , C07D337/12
摘要： Antitussives containing as the active ingredient tricyclic compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R is hydrogen, substituted or unsubstituted lower alkyl, or the like; X -X -X is CR =CR -CR =CR (wherein R , R , R and R are each independently hydrogen, substituted or unsubstituted lower alkyl, or the like) or the like; Y is -CH2S- or the like; and R is hydrogen, substituted or unsubstituted lower alkyl, or the like.
摘要翻译：含有作为活性成分的由通式（I）表示的三环化合物或其药理学上可接受的盐的镇咳剂：（I）其中R 1是氢，取代或未取代的低级烷基等; X 1 -X 2 -X 3是CR 5 = CR 6 -CR 7 = CR 8（其中R 5，R 6，R 7，和R 8各自独立地为氢，取代或未取代的低级烷基等）等; Y是-CH 2 S-等; 和R 2是氢，取代或未取代的低级烷基等。

7. 发明申请

WO2004052847A3 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS 审中-公开
标题翻译：三环类甾体激素核受体调节剂
公开(公告)号：WO2004052847A3
公开(公告)日：2004-09-10
申请号：PCT/US0316213
申请日：2003-06-13
申请人： LILLY CO ELI , COGHLAN MICHAEL JOSEPH , GREEN JONATHAN EDWARD , GRESE TIMOTHY ALAN , JADHAV PRABHAKAR KONDAJI , MATTHEWS DONALD PAUL , STEINBERG MITCHELL IRVIN , FALES KEVIN ROBERT , BELL MICHAEL GREGORY
发明人： COGHLAN MICHAEL JOSEPH , GREEN JONATHAN EDWARD , GRESE TIMOTHY ALAN , JADHAV PRABHAKAR KONDAJI , MATTHEWS DONALD PAUL , STEINBERG MITCHELL IRVIN , FALES KEVIN ROBERT , BELL MICHAEL GREGORY
IPC分类号： C07D295/08 , A61K31/015 , A61K31/03 , A61K31/04 , A61K31/045 , A61K31/055 , A61K31/09 , A61K31/10 , A61K31/335 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/435 , A61K31/4402 , A61K31/4406 , A61K31/4436 , A61K31/4453 , A61K31/4965 , A61K31/5377 , A61K31/55 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/08 , A61P3/10 , A61P3/12 , A61P3/14 , A61P5/26 , A61P5/38 , A61P5/46 , A61P7/04 , A61P7/10 , A61P9/00 , A61P9/02 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P17/10 , A61P19/02 , A61P19/10 , A61P25/02 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07C22/04 , C07C22/08 , C07C25/22 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C205/06 , C07C205/35 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/08 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07D209/08 , C07D209/34 , C07D211/18 , C07D213/127 , C07D213/16 , C07D213/65 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/64 , C07D233/84 , C07D235/26 , C07D241/12 , C07D241/20 , C07D241/26 , C07D261/08 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/092 , C07D295/22 , C07D295/26 , C07D313/14 , C07D333/80 , C07D337/12 , C07D337/14 , C07D401/06 , C07D403/06 , C07D405/04 , C07D405/06 , C07D409/04 , C07D471/04 , C07D487/04 , C07D491/044 , A61K31/18 , A61K31/553 , C07D235/14 , C07D313/12
CPC分类号： C07D213/16 , C07C22/04 , C07C22/08 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C69/00 , C07C69/618 , C07C69/65 , C07C205/06 , C07C205/34 , C07C205/35 , C07C211/28 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/08 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07C2601/02 , C07C2603/32 , C07C2603/40 , C07C2603/78 , C07C2603/86 , C07D209/08 , C07D209/34 , C07D211/96 , C07D213/06 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/68 , C07D233/84 , C07D235/26 , C07D241/12 , C07D241/20 , C07D261/08 , C07D261/10 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/088 , C07D295/26 , C07D313/12 , C07D333/78 , C07D333/80 , C07D337/12 , C07D401/06 , C07D405/06 , C07D409/04 , C07D471/04 , C07D471/06 , C07D487/04 , C07D491/044
摘要： The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).
摘要翻译：本发明涉及治疗对类固醇激素核受体调节敏感的病理性疾病的方法，该方法包括给需要治疗的患者施用有效量的式（I）化合物或其药学上可接受的盐。此外，本发明提供了式（I）的新型药物化合物，包括其药学上可接受的盐，以及包含式（I）化合物作为活性成分的药物组合物。

8. 发明申请

WO2004052847A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS 审中-公开
公开(公告)号：WO2004052847A2
公开(公告)日：2004-06-24
申请号：PCT/US2003/016213
申请日：2003-06-13
申请人： ELI LILLY AND COMPANY , COGHLAN, Michael, Joseph , GREEN, Jonathan, Edward , GRESE, Timothy, Alan , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , STEINBERG, Mitchell, Irvin , FALES, Kevin, Robert , BELL, Michael, Gregory
发明人： COGHLAN, Michael, Joseph , GREEN, Jonathan, Edward , GRESE, Timothy, Alan , JADHAV, Prabhakar, Kondaji , MATTHEWS, Donald, Paul , STEINBERG, Mitchell, Irvin , FALES, Kevin, Robert , BELL, Michael, Gregory
IPC分类号： C07C311/00
CPC分类号： C07D213/16 , C07C22/04 , C07C22/08 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C69/00 , C07C69/618 , C07C69/65 , C07C205/06 , C07C205/34 , C07C205/35 , C07C211/28 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/08 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07C2601/02 , C07C2603/32 , C07C2603/40 , C07C2603/78 , C07C2603/86 , C07D209/08 , C07D209/34 , C07D211/96 , C07D213/06 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/68 , C07D233/84 , C07D235/26 , C07D241/12 , C07D241/20 , C07D261/08 , C07D261/10 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/088 , C07D295/26 , C07D313/12 , C07D333/78 , C07D333/80 , C07D337/12 , C07D401/06 , C07D405/06 , C07D409/04 , C07D471/04 , C07D471/06 , C07D487/04 , C07D491/044
摘要： The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).
摘要翻译：本发明涉及治疗对类固醇激素核受体调节敏感的病理学障碍的方法，包括向有需要的患者施用有效量的式（I）化合物或其药学上可接受的盐。此外，本发明提供新的式（I）的药物化合物，包括其药学上可接受的盐，以及包含作为活性成分的式（I）的化合物的药物组合物。

9. 发明申请

WO1989003212A1 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS 审中-公开
标题翻译： 3,5-二羟基-6,8-非壬二酸和衍生物作为高效液相色谱
公开(公告)号：WO1989003212A1
公开(公告)日：1989-04-20
申请号：PCT/US1987002623
申请日：1987-10-13
申请人： PFIZER INC. , McCARTHY, Peter, A. , WALKER, Frederick, J.
发明人： PFIZER INC.
IPC分类号： A61K31/20
CPC分类号： C07D337/12 , C07C45/29 , C07C45/513 , C07C47/232 , C07C47/238 , C07C47/24 , C07C59/42 , C07C59/48 , C07C59/54 , C07C59/90 , C07C2603/32 , C07D311/82 , C07D335/12
摘要： Variously substituted 3,5-dihydroxy-6,8-nonadienoic acids and esters, are blood cholesterol lowering agents and so are useful in the prevention and treatment of cardiovascular diseases such as atherosclerosis.

10. 发明申请

WO1987005014A1 TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION CONTAINING THEM 审中-公开
标题翻译：三氯化合物，其制备方法和含有它们的药物组合物
公开(公告)号：WO1987005014A1
公开(公告)日：1987-08-27
申请号：PCT/JP1987000085
申请日：1987-02-10
申请人： DAINIPPON PHARMACEUTICAL CO., LTD. , UNO, Hitoshi , KUROKAWA, Mikio , SATO, Fuminori , NARUTO, Shunsuke , HOSOKI, Kanoo , TAKEYAMA, Kunihiko
发明人： DAINIPPON PHARMACEUTICAL CO., LTD.
IPC分类号： C07C83/10
CPC分类号： C07D409/12 , C07D213/38 , C07D307/14 , C07D307/52 , C07D309/04 , C07D333/20 , C07D333/76 , C07D337/12 , C07D409/14
摘要： Compounds represented by general formula (I), (wherein Y-Z represents (II), -CH=CH- or -CH2CH2-, R1 and R2 each represents a substituent, R3 represents hydrogen, alkyl or alkoxy, R4 represents hydrogen, alkyl, optionally substituted alkenyl, alkynyl, optionally substituted cycloalkyl, phenyl, monocyclic heteroaryl or substituted alkyl, R5 represents phenyl, substituted phenyl or monocyclic heteroaryl, W represents alkylene, X represents a single bond, optionally substituted alkylene, or alkylene interrupted by a group selected from among -O-, -S-, (III) and -CH=CH- or bound to R5 through one of these groups, and a represents an integer of 0 to 2), salts thereof, a process for their preparation, and a medicinal composition containing them. The compounds and the salts show such a strong calcium-antagonistic effect that they are useful for prophylaxis and/or treatment of hypertensive and/or ischemic heart diseases.
摘要翻译：由通式（I）表示的化合物（其中YZ表示（II），-CH = CH-或-CH2CH2-，R1和R2各自表示取代基，R3表示氢，烷基或烷氧基，R4表示氢，烷基，取代的烯基，炔基，任选取代的环烷基，苯基，单环杂芳基或取代的烷基，R 5表示苯基，取代的苯基或单环杂芳基，W表示亚烷基，X表示单键，任选取代的亚烷基或被选自 -O - ， - S - ，（III）和-CH = CH-或通过这些基团之一与R5结合，a表示0至2的整数），其盐，其制备方法和药用包含它们的组合。化合物和盐显示出如此强的钙拮抗作用，它们可用于预防和/或治疗高血压和/或缺血性心脏病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式